comparemela.com

Latest Breaking News On - Matthew weston - Page 7 : comparemela.com

AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript

NOVARTIS AG : Buy rating from UBS -February 06, 2024 at 03:08 am EST

In his latest research note, analyst Matthew Weston confirms his positive recommendation. The broker UBS is keeping its Buy rating. The target price remains set at CHF 104.

vimarsana © 2020. All Rights Reserved.